- Cape businessman known for starting NARS dies at 49 (2/23/17)9
- Apparent punch at girls basketball game propels lawmaker into action (2/21/17)4
- Business notebook: Owners ready to roll out the Barrel 131 (2/20/17)7
- Japanese restaurant up and running; owner surprised by fondness of sushi here (2/24/17)1
- SoutheastHEALTH, Washington University School of Medicine announce collaboration (2/24/17)23
- Missouri bill would limit transgender school bathroom access (2/22/17)48
- City issues precautionary boil order near Arena Park (2/23/17)
- Former KFVS12 reporter talks about recovery from eating disorder (2/23/17)11
- $22M bond issue would alter Jackson schools (2/22/17)13
- Two men crack market with local cage-free eggs (2/26/17)12
Common antibiotic slows Gehrig's disease in mice
An ordinary antibiotic slowed the progression of Lou Gehrig's disease in mice, suggesting a potential new approach for treating people, researchers report.
The disease, formally known as amyotrophic lateral sclerosis or ALS, attacks nerve cells that control movement. As these cells degenerate, an affected person becomes progressively paralyzed. Most cases appear between the ages of 40 and 70, and death follows an average of four years after symptoms appear.
The antibiotic, minocycline, was shown recently to prolong the lives of mice with a version of Huntington's disease, another neurodegenerative disorder. It is now being tested against Huntington's in people.
Minocycline has been used as an antibiotic for 30 years in people and has a good track record for safety, even when taken for long periods, said Dr. Robert Friedlander of Brigham and Women's Hospital in Boston, senior author of the new study.
The work is reported in the May 2 issue of the journal Nature. Researchers studied mice with a version of ALS created by genetic mutations.
Daily injections of minocycline delayed appearance of the disease and prolonged life. Treated mice lived about 137 days, compared to 126 days for untreated mice.
The drug's effect has nothing to do with its antibiotic ability. Rather, researchers found that minocycline treatment reduces production of a protein within nerve cells that can lead to cell death.